Sign up to save your podcasts
Or
Share Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Featuring an interview with Dr Neel Pasricha, including the following topics:
- Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
- Association of corneal toxicities with ADCs (4:56)
- Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
- Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
- Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
- Other ocular toxicities associated with cancer therapies (24:26)
- Prevention and management of corneal toxicity (33:58)
- Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
- General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)
CME information and select publications
View all episodes
By Dr Neil Love
4.6
112112 ratings
Featuring an interview with Dr Neel Pasricha, including the following topics:
- Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
- Association of corneal toxicities with ADCs (4:56)
- Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
- Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
- Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
- Other ocular toxicities associated with cancer therapies (24:26)
- Prevention and management of corneal toxicity (33:58)
- Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
- General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)
CME information and select publications
More shows like Research To Practice | Oncology Videos
View all
JAMA Editors' Summary
138 Listeners
Gastrointestinal Cancer Update
17 Listeners
Lung Cancer Update
30 Listeners
Prostate Cancer Update
13 Listeners
Breast Cancer Update
69 Listeners
Gynecologic Oncology Update
13 Listeners
Hematologic Oncology Update
76 Listeners
Dermatologic Oncology Update
0 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
501 Listeners
ASCO Daily News
57 Listeners
White Coat Investor Podcast
2,431 Listeners
The Curbsiders Internal Medicine Podcast
3,340 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
The ONS Podcast
200 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners